Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis in Iran
Conclusion: Compared to no treatment, Teriparatide was indicated to be more costly and associated with fewer fractures, more life-years, and more QALYs. The result showed that Teriparatide may be considered a cost-effective intervention when targeted to the appropriate patients.
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Forteo | Iran Health | Men | Menopause | Middle East Health | Orthopaedics | Osteoporosis | Study | Women